Last update March 5, 2021
Very Low Risk
We do not have alternatives for Certolizumab since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Certolizumab is also known as
Certolizumab in other languages or writings:
Certolizumab belongs to these groups or families:
Main tradenames from several countries containing Certolizumab in its composition:
|Oral Bioavail.||≈ 0||%|
|Tmax||54 - 171||hours|
|Theoretical Dose||0 - 0.01||mg/Kg/d|
|Relative Dose||0 - 0.15||%|
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is a humanised monoclonal antibody directed against TNFα (tumour necrosis factor alpha) that is used for treatment of autoimmune diseases like Rheumatoid Arthritis, Axial spondyloarthritis, Ankylosing spondylitis, Psoriatic arthritis and Crohn's Disease unresponsive to conventional treatment.
Injected subcutaneous administration every 2 weeks for months.
Probably because of a high molecular weight, no detectable traces or very low concentrations have been found in mother's milk (Morita 2018, Matro 2018, EMA 2018, Clowse 2017, Forger 2016, Mahadevan 2013).
It is not absorbed by the gut which is even more protective for the nursing infant.
No harm effect has been shown among breastfed infants whose mothers were treated with this medication (Clowse 2017, Mahadevan 2013 & 2012).
The manufacturer (EMA 2018) and expert authors and medical associations consider it compatible with breastfeeding (Hale, Owczarek 2020, Sammaritano 2020, Picardo 2019, Mahadevan 2019 y 2017, Amin 2018, Matro 2018, Clowse 2017, Flint 2016, Gotestam-EULAR 2016, Briggs 2015, Damas 2015, Chaparro 2015, Nielsen 2014, Gisbert 2013 y 2011, Yarur 2013, Mahadevan 2011, van der Woude 2010, Fischer 2010).
It may be prudent to avoid its use in the two post-partum weeks since significant excretion into the milk within the first 3 - 4 days after delivery and absorption by the infant is possible.
See below the information of these related products: